SAFE HARBOR

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Investor Events” section of our website at ir.perkinelmer.com.
Combination with BioLegend: Accelerating Legendary Discoveries in Precision Medicine

- **BioLegend** is a global provider of high-quality antibodies and reagents
- 2022e revenues of ~$380M with mid-teens+ CAGR (excl. synergies) expected going forward
- Purchase price of $5.25B: $2.2B stock consideration with remainder funded by newly issued debt and cash on-hand
  - Committed to remaining investment grade
- Enhanced combined growth and margin profile with $0.30 adj. EPS accretion expected in Year 1 & >$0.50 in Year 2
  - High single-digit adj. ROIC anticipated by Year 6
- Expected to **close by year-end** 2021

Transformative for PerkinElmer life science with additional synergies in diagnostics
**BioLegend: Strong Innovation Drives Attractive Profile**

**BEST-IN-CLASS GLOBAL INNOVATOR of antibodies and reagents**

- **Total Addressable Market**
  - ~$6B
  - ~10% Projected Market Growth (2021-2024)

**COMPETITIVE POSITIONING**

- Flow Cytometry
- Proteogenomics
- Magnetic Cell Separation
- Immunoassays
- Recombinant Proteins
- Bioprocessing

- Global provider of innovative antibodies
- Gaining momentum in emerging, high-growth areas of proteogenomics, recombinant proteins, and bioprocessing
- >1,000 new product introductions annually
- Expect mid-teens+ organic revenue growth (excl. synergies)

---

**Revenue Split**

- 55% North America
- 25% Europe & RoW
- 20% Asia Pacific

**2022e Revenue**

- $380M
- 100% Recurring Revenue
- Accretive Margin Profile

**Employees**

- >700

**Customers**

- 10K

**Countries**

- 130

*Source: External Advisors and Internal Company Estimates*
**STRATEGIC RATIONALE**

- **High-Growth, High-Margin Markets**
  Expands PKI into fast growing, high margin, antibody focused markets. Increases PKI’s overall mix of recurring revenue

- **Global Reagents CoE for Legendary Discovery**
  BioLegend’s San Diego HQ will become the content development engine for reagents across the life science portfolio

- **Support PKI Dx Development**
  Leveraging PKI’s position in Dx and broad commercial reach will expand impact and accelerate NPIs in high-growth opportunities such as decentralized & multiplex diagnostics

**VALUE CREATION**

- Will create a >$1.5B life science franchise with ~$700M in life science research reagent revenue by 2022
- Dedicated direct sales teams will drive growth globally, leveraging scale and customer relationships, esp. outside U.S.

- **Global Scale & Reach**
- **Acceleration of New Product Introductions (NPIs)**
  Combined expertise and innovation engine will accelerate pace of NPIs in DAS, Dx, and new high-growth areas such as biologics, cell & gene therapy & single cell analysis

- **Further Elevates Strong Franchises**
  The combination will drive powerful brand equity with best-in-class solutions across respected complementary brands

**TARGETING $100M+ OF ANNUALIZED REVENUE SYNERGIES BY YEAR 5**
CREATES A TRANSFORMATIVE PLAYER IN ANTIBODY & RESEARCH REAGENTS

Combined Research Reagent Portfolio

~$700M 2022e Revenue

+LDD Projected Growth

>55% of Life Science Revenue From Large Molecule

Global CoE for Life Science Reagents
Taking PKI’s Compelling Financial Profile to the Next Level

Current Medium-Term Financial Outlook

- **Organic Growth**: 5 - 7%
- **% Recurring Revenue**: Mid-70%
- **Operating Margins**: 23%

Pro Forma Outlook

- + 100 bps
- + 200 bps
- + 300 bps

>80% of Combined Company in Life Science & Diagnostics
Scale with an Attractive Financial Profile

Funding
- Fully underwritten bridge financing from Goldman Sachs
- Existing BioLegend shareholders to receive $2.2B in equity
- Expect to issue multi-tranche debt & utilize cash-on-hand

Pro Forma Leverage
- Expect to de-lever to <3.0x net leverage within 18-24 months
- Committed to maintain Investment Grade ratings

Adjusted EPS Accretion
- $0.30 expected in Year 1
- >$0.50 expected in Year 2

Returns
- HSD ROIC expected in Year 6
PUTTING IT ALL TOGETHER

BEST-IN-CLASS ADVANCED REAGENTS COMPANY

Enabling Legendary Discovery

TRANSFORMATIVE COMBINATION

Leading with Science from Research to Cure

STRONG PRO-FORMA PROFILE

Faster Revenue Growth & Higher Margins

ATTRACTIVE OUTLOOK

Adj. EPS Accretion
$0.30 Year 1
>$0.50 Year 2

ACCELERATING RESEARCH TO CURE